✦ LIBER ✦

130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

✍ Scribed by C. Parker; D. Heinrich; S.I. Helle; J.M O'Sullivan; S Fossä; A. Chodacki; T. Demkow; J. Logue; M. Seke; A. Widmark; D.C. Johannessen; S. Nilsson; P. Hoskin; D. Bottomley; A. Solberg; N.D. James; I. Syndikus; S.A. Wedel; J. Kliment; A. Cross; C.G O'Bryan-Tear; J Garcia-Vargas; O. Sartor

Book ID: 119624066
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 107 KB
Volume: 11
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(12)60129-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

684 RADIUM-223 CHLORIDE (ALPHARADIN) IMP

684 RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES A PHASE III RANDOMIZED TRIAL (ALSYMPCA)

✍ Sartor, Oliver; Heinrich, Daniel; Helle, Svein Inge; O'Sullivan, Joe M.; Chodack 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 50 KB

Overall Survival Benefit of Radium-223 C

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

✍ C. Parker; D. Heinrich; J.M. O'Sullivan; S. Fossa; A. Chodacki; T. Demkow; A. Cr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

101 Updated analysis of radium-223 dichl

101 Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) and bone metastases

✍ Heinrich, D.; Helle, S.I.; Chodacki, A.; Wiechno, P.; Garcia-Vargas, J.; Staudac 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Radium-223 Chloride Safety and Use of Ex

Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase III Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases

✍ Sandler, H.M.; Nilsson, S.; Parker, C.; Garcia-Vargas, J.; Staudacher, K.; Hoski 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 97 KB

Radium-223 Dichloride (Ra-223) Impact on

Radium-223 Dichloride (Ra-223) Impact on Skeletal-Related Events, External Beam Radiation Therapy (EBRT), and Pain in Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases: Updated Results From the Phase 3 ALSYMPCA Trial

✍ Michalski, J.; Sartor, O.; Parker, C.; Shan, M.; Garcia-Vargas, J.; Aksnes, A.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Effect of radium-223 dichloride on sympt

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

✍ Sartor, Oliver; Coleman, Robert; Nilsson, Sten; Heinrich, Daniel; Helle, Svein I 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 527 KB